

www.cocrystalpharma.com - Nasdaq: COCP

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company employing its unique structure-based technologies and Nobel Prize-winning expertise to create and develop first- and best-in-class broad-spectrum antiviral drugs for serious and/or chronic diseases. These technologies are designed to efficiently deliver small-molecule therapeutics that target the viral replication process and are safe, effective and convenient to administer. Cocrystal's development programs include COVID-19, influenza, hepatitis C and gastroenteritis caused by norovirus.

Cocrystal expects to initiate enrollment in a Phase 1 study in influenza A in 1Q22 and has a goal to begin clinical trials in two COVID-19 programs in 2022.

Investment Highlights

Applying proprietary structure-based drug discovery platform to develop broad spectrum direct acting antivirals with high barriers to resistance.

Large market opportunities for the treatment of acute and chronic viral diseases including COVID-19, influenza, hepatitis C and norovirus gastroenteritis.

Regulatory clearance to initiate Phase 1 trial for potent, broad-spectrum treatment for seasonal and pandemic influenza A.

Advancing 3 COVID-19 programs with goal of initiating two Phase 1 trials with compounds for intranasal/pulmonary delivery and also oral delivery in 2022.

Product candidates are tested for multiple routes of delivery including oral, inhalation and injection.

Robust development pipeline of antiviral programs including a Merck collaboration for pandemic and seasonal influenza.

Seasoned leadership includes biotech veterans with proven success in drug discovery and development, business and finance, and two Nobel laureates.

Cost-efficient business model with no debt and capital sufficient to fund planned operations.

Technology Overview and Development Pipeline

- **Structure-based drug discovery platform** featuring proprietary structural biology, enzymology and medicinal chemistry expertise.
- **3-D structure of inhibitor complexes** at near-atomic resolution helps to identify novel binding sites and allows for the rapid turnaround of structural information through highly automated x-ray data processing and refinement.
- **Broad spectrum direct acting antiviral activity and high barrier to resistance that specifically block viral replication.**
- **Market-driven development** programs aimed at expanding treatment options.

Program		Discovery	Preclinical	Phase 1	Phase 2	Phase 3
COVID-19	Oral Protease Inhibitor	[Progress bar]			Planned Phase 1 trial initiation in 2022	
COVID-19 (Licensed)	CDI-45205 Protease Inhibitor	[Progress bar]			Planned Phase 1 trial initiation in 2022	
COVID-19	Replication Inhibitors	[Progress bar]			Discovery ongoing	
Influenza A	CC-42344 PB2 Inhibitor	[Progress bar]			Planned Phase 1 trial initiation in 1Q22	
Influenza A/B	Influenza A/B Inhibitor	[Progress bar]			In collaboration with 	
Hepatitis C (HCV)	CC-31244 Pan-genotypic NS5B NNI	[Progress bar]			Available for partnering	
Norovirus Gastroenteritis	Replication and Protease Inhibitors	[Progress bar]			Preclinical lead selection planned for 2022-2023	

Development Programs

Influenza A/B Collaboration with Merck




Potent, broad-spectrum influenza preclinical candidates expected to be active against pandemic and seasonal influenza and existing drug-resistant influenza strains.

January 2019: Announced exclusive worldwide license and collaboration agreement with Cocrystal eligible to receive

up to \$156 million in milestone payments plus royalties on future net product sales.

January 2021: Announced the completion of all research obligations under the agreement to discover and develop proprietary influenza A/B antiviral agents. Merck assumed sole responsibility for continued product development and commercialization activities.

1Q22: Planned development update of compounds under Merck collaboration agreement.



Pandemic and Seasonal Influenza A Program

Addressing major U.S. and global concern: Significant unmet need with drug-resistant variants against currently approved therapies

- Exhibits broad-spectrum activity against seasonal and pandemic strains
- Favorable preclinical safety profile and pharmacokinetic properties
- Multiple routes of administration include oral, inhalation and injection

2Q21: Completed IND-enabling studies and selected clinical CRO

Oct. 6, 2021: Received regulatory clearance to begin Phase 1 trial with enrollment expected to begin in 1Q22.

COVID-19 Programs

Developing multiple preclinical leads targeting viral replication process with potential COVID-19 treatments.

Cocrystal preclinical leads show broad-spectrum activity against SARS-CoV-2 and its variants

1. Oral broad-spectrum protease inhibitor

- Expects to select preclinical lead by year end 2021 followed by initiation of scale up synthesis
- **2022:** Planned initiation of Phase 1 trial

2. Oral broad-spectrum replication inhibitors

- Lead discovery ongoing

3. Intranasal broad-spectrum protease inhibitor, CDI-45205

- Licensed from Kansas State University Research Foundation (KSURF)
- Completed exploratory toxicology study
- Initiated scale-up synthesis and process chemistry development
- **2022:** Planned initiation of Phase 1 trial

Norovirus Program

Broad-spectrum oral protease and replication inhibitors Estimated \$60 billion worldwide annual cost due to direct healthcare expenses and loss of productivity

- Ongoing proof-of-concept animal study with selected inhibitors

Preclinical lead selection planned for 2022-2023

Hepatitis C Program

CC-31244, a liver-targeting, orally administered, best-in-class non-nucleoside inhibitor (NNI) effective against known NNI drug-resistant variants.

- Favorable Phase 2a study results in combination therapy

Seeking partner for further development

Management Team

Sam Lee, Ph.D. – President & Interim Co-CEO

25+ years of anti-infective drug discovery research experience; played a key role in the early development of phosphoinositide 3-kinase (PI3K) delta inhibitors

James J. Martin – CFO & Interim Co-CEO

25+ years of finance and management experience including providing financial leadership to commercial-stage, publicly traded health science companies

Scientific Advisory Board

Roger Kornberg, Ph.D.

Chairman of Board of Directors
Chief Scientist, SAB Chair
Professor, Stanford University
School of Medicine
Nobel Laureate

Michael Levitt, Ph.D.

Professor, Stanford University
School of Medicine
Nobel Laureate

Baek Kim, Ph.D.

Director of Center for Drug
Discovery, Emory University

Bob Lehman, Ph.D.

Professor (Emeritus), Stanford
University School of Medicine

Gary Schoolnik, M.D.

Professor (Emeritus), Stanford
University School of Medicine

Roland Strong, Ph.D.

Professor, Fred Hutchinson Cancer
Research Center

Christophe Verlinde, Ph.D.

Professor (Emeritus), University
of Washington

Investor Contact

LHA Investor Relations

Jody Cain

jcain@lhai.com / 310-691-7100

Financial Snapshot

- \$61.6 million as of September 30, 2021
- No debt
- Common stock only, no preferred
- Lean efficient operations
- Cash sufficient to fund planned operations

The information contained herein was obtained from the management of Cocrystal and other sources LHA believes to be reliable. LHA is engaged by Cocrystal as its investor relations firm. This document contains forward-looking statements, including statements regarding future effectiveness of drug candidates, the achievement of value-driving milestones in each of Cocrystal's programs, planned events and the expected results of collaboration with Merck, including future milestone payments. Investors should consult the "Risk Factors" in the Form 10-K for the year ended December 31, 2020, as updated by subsequent Form 10-Qs. The forward-looking statements in this document speak only as of the date hereof, and there is no intent or obligation to revise or update publicly any forward-looking statement except as required by law. This document shall not constitute an offer to sell, or the solicitation of an offer to buy, securities.

December 2021